| 产品编号 | bs-0984R |
| 英文名称 | LHR Rabbit pAb |
| 中文名称 | 促黄体生成素受体抗体 |
| 别 名 | LHCGR; Gonadotropin receptor; CGR; hCG receptor; FLJ41504; Gpcr19-rs1; GTHR-II; HHG; LCGR; LGR2; LH-R; LH/CG R; LH/CG-R; LH RECEPTOR; LH/CGR; LHRHR; LSH R; LSH-R; LSHR_MOUSE; Luteinizing hormone receptor; Luteinizing hormone/choriogonadotropin receptor; luteinizing hormone/choriogonadotropin receptor; Lutropin choriogonadotropic hormone receptor; Lutropin choriogonadotropic receptor; Lutropin-choriogonadotropic hormone receptor; ULG5. |
 |
Specific References (2) | bs-0984R has been referenced in 2 publications.
[IF=6.71] Umehara, Takashi, et al. "The acceleration of reproductive aging in Nrg1flox/flox; Cyp19‐Cre female mice." Aging Cell (2017). IHC-P ; Mouse.
[IF=4.161] Kinnear Hadrian M. et al. Presence of ovarian stromal aberrations after cessation of testosterone therapy in a transgender mouse model. BIOL REPROD. 2023 Feb;: IHC ; Mouse.
|
| 研究领域 | 神经生物学 生长因子和激素 内分泌病 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | (predicted: Mouse,Rat) |
| 产品应用 | IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 76 kDa |
| 检测分子量 | |
| 细胞定位 | 细胞膜 |
| 性 状 | Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from mouse CG Receptor: 501-600/700 <Cytoplasmic> |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 缓 冲 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存条件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 |
This gene encodes the receptor for both luteinizing hormone and choriogonadotropin. This receptor belongs to the G-protein coupled receptor 1 family, and its activity is mediated by G proteins which activate adenylate cyclase. Mutations in this gene result in disorders of male secondary sexual character development, including familial male precocious puberty, also known as testotoxicosis, hypogonadotropic hypogonadism, Leydig cell adenoma with precocious puberty, and male pseudohermaphtoditism with Leydig cell hypoplasia. [provided by RefSeq] Function: Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Subcellular Location: Cell membrane; Multi-pass membrane protein. Tissue Specificity: Gonadal and thyroid cells. DISEASE: Familial male precocious puberty (FMPP) [MIM:176410]: In FMPP the receptor is constitutively activated. Note=The disease is caused by mutations affecting the gene represented in this entry. Luteinizing hormone resistance (LHR) [MIM:238320]: An autosomal recessive disorder characterized by unresponsiveness to luteinizing hormone, defective sexual development in males, and defective follicular development and ovulation, amenorrhea and infertility in females. Two forms of the disorder have been defined in males. Type 1 is a severe form characterized by complete 46,XY male pseudohermaphroditism, low testosterone and high luteinizing hormone levels, total lack of responsiveness to luteinizing and chorionic gonadotropin hormones, lack of breast development, and absent development of secondary male sex characteristics. Type 2, a milder form, displays a broader range of phenotypic expression ranging from micropenis to severe hypospadias. Note=The disease is caused by mutations affecting the gene represented in this entry. Similarity: Belongs to the G-protein coupled receptor 1 family. FSH/LSH/TSH subfamily. Contains 6 LRR (leucine-rich) repeats. Contains 1 LRRNT domain. Database links: Entrez Gene: 3973 Human Omim: 152790 Human SwissProt: P22888 Human Unigene: 468490 Human Unigene: 11216 Rat |
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
